Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 4/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.53 |
| ▸ | MET | P08581 | 3/20 | 0.51 |
| ▸ | AXL | P30530 | 3/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.47 |
| ▸ | KDR | P35968 | 8/20 | 0.47 |
| ▸ | KIT | P10721 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5824762 | 0.87 | SRC (0.54) | SRCTGFBR1FGFR2METAXL | |
| SCHEMBL5825766 | 0.87 | SRC (0.55) | SRCTGFBR1METPDGFRAKDR | |
| SCHEMBL5824386 | 0.87 | KDR (0.56) | SRCTGFBR1FGFR2METAXL | |
| SCHEMBL5825052 | 0.85 | FGFR2 (0.53) | SRCTGFBR1FGFR2METAXL | |
| SCHEMBL5825492 | 0.85 | KDR (0.57) | SRCTGFBR1FGFR2METAXL | |
| SCHEMBL5825517 | 0.85 | PDGFRA (0.54) | SRCTGFBR1FGFR2METAXL | |
| SCHEMBL5825420 | 0.84 | SRC (0.54) | SRCTGFBR1FGFR2METAXL | |
| SCHEMBL5824545 | 0.84 | FGFR2 (0.52) | SRCTGFBR1FGFR2METAXL | |
| SCHEMBL5825182 | 0.84 | SRC (0.56) | SRCTGFBR1FGFR2METAXL | |
| SCHEMBL5825443 | 0.84 | FGFR2 (0.50) | SRCTGFBR1FGFR2METAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135466-B2 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-21 | — | — | US | disclosed |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | SRC 272/4885TGFBR1 196/4885FGFR2 90/4885 |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | SRC 195/4885TGFBR1 295/4885FGFR2 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.